Brain

M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports

BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of M2M Healthcare?According to Valuates Reports, The global...

M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports

BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of M2M Healthcare?According to Valuates Reports, The global...

Digital Medical Partnerships Market Size to Reach USD 3.76 Billion by 2031 Driven by Healthcare Digital Transformation and Connected Care Growth | Valuates Reports

BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of Digital Medical Partnerships?According to Valuates Reports, The...

Digital Medical Partnerships Market Size to Reach USD 3.76 Billion by 2031 Driven by Healthcare Digital Transformation and Connected Care Growth | Valuates Reports

BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of Digital Medical Partnerships?According to Valuates Reports, The...

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance...

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

Builds on positive Phase I safety data and represents a key value-inflection milestone for the CompanyAdvances a potentially disease-modifying approach...

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional...

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies

Red Light Holland’s Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

error: Content is protected !!